PTCT vs BMRN Stock Comparison: AI Score, Valuation, Performance and Upside
PTC Therapeutics and BioMarin both build their businesses around treating rare genetic disorders, but BioMarin has a longer track record and broader portfolio of approved therapies, while PTC Therapeutics is earlier in scaling its gene therapy and Duchenne-focused pipeline.
PTCT offers exposure to an earlier-stage rare disease pipeline with turnaround potential, while BMRN offers a more established, diversified rare disease commercial base. The decision hinges on whether you prefer BioMarin's broader approved portfolio or PTC's earlier-stage growth optionality.
PTCT holds the edge across 4 of 5 key metrics in this comparison. PTCT has delivered stronger 1-year price return (+21.99% vs +12.80%), though BMRN has the better forward P/E setup (10.20x vs 28.72x for PTCT). PTCT leads on both revenue growth (101.50%) and operating margin (41.32%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +38.30% for PTCT and +36.51% for BMRN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a pipeline-driven rare disease biotech with gene therapy optionality
- Believe Duchenne muscular dystrophy treatments represent an underpenetrated therapeutic category
- Are comfortable with the concentration risk of a smaller rare disease commercial base
- See global expansion of existing rare disease franchises as a durable growth driver
- Prefer a rare disease biotech with a longer track record of commercial execution
- Value diversification across multiple approved rare disease therapies rather than reliance on a single franchise
- Believe achondroplasia and enzyme replacement franchises still have room to grow
- Want exposure to rare disease biotech without the binary risk of an unapproved gene therapy pipeline
| Metric | PTCT | BMRN |
|---|---|---|
| AI scorei | 62.4 | 27.4 |
| AI ranki | #114 | #2443 |
| Latest closei | $69.47 | $66.53 |
| 1M returni | -5.23% | +11.05% |
| 6M returni | +1.33% | +9.84% |
| 1Y returni | +21.99% | +12.80% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PTCT | BMRN |
|---|---|---|
| 1Y ago | $12.2K (+22.0%) started 2025-09-08 | $11.72K (+17.2%) started 2025-09-04 |
| 5Y ago | $16.35K (+63.5%) started 2021-09-08 | $8.55K (-14.5%) started 2021-09-07 |
| 10Y ago | $84.73K (+747.3%) started 2016-09-08 | $6.96K (-30.4%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | PTCT | BMRN |
|---|---|---|
| Market capi | $5.99B | $12.91B |
| Trailing P/Ei | N/A | 180.24 |
| Forward P/Ei | 28.72 | 10.20 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 6.62 | 4.66 |
| Analyst targeti | $99.29 | $91.04 |
| Target upsidei | +38.30% | +36.51% |
| Metric | PTCT | BMRN |
|---|---|---|
| Revenue growthi | 101.50% | 19.90% |
| Earnings growthi | N/A | -81.30% |
| EPS growthi | N/A | -81.30% |
| FCF margini | -28.43% | +2.50% |
| Operating margini | 41.32% | 21.16% |
| Profit margini | -3.81% | 2.14% |
| ROIC proxyi | N/A | 1.18% |
| Return on equityi | N/A | 1.18% |
| Dividend yieldi | N/A | N/A |
| Betai | 0.55 | 0.23 |
| Debt/equityi | N/A | 66.47 |
| Current ratioi | 3.39 | 2.39 |
| Quick ratioi | 3.20 | 1.16 |
Over the past year, PTCT and BMRN have moved weakly in the same direction (correlation of 0.32), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PTCT | BMRN |
|---|---|---|---|
| 1Y | Growthi | +21.99% | +17.23% |
| CAGRi | +22.01% | +17.26% | |
| Volatilityi | 40.27% | 35.19% | |
| Sharpe ratioi | 0.58 | 0.49 | |
| Sortino ratioi | 0.87 | 0.89 | |
| Max drawdowni | 27.17% | 22.49% | |
| Current drawdowni | 22.42% | 5.28% | |
| Avg drawdowni | 12.60% | 8.31% | |
| Ulcer Indexi | 15.01% | 9.58% | |
| Max daily dropi | 9.94% | 4.35% | |
| Max wkly dropi | 12.49% | 8.75% | |
| 5Y | Growthi | +63.47% | -14.50% |
| CAGRi | +10.33% | -3.09% | |
| Volatilityi | 55.08% | 32.96% | |
| Sharpe ratioi | 0.38 | -0.07 | |
| Sortino ratioi | 0.55 | -0.10 | |
| Max drawdowni | 69.42% | 57.64% | |
| Current drawdowni | 22.42% | 43.27% | |
| Avg drawdowni | 23.60% | 28.92% | |
| Ulcer Indexi | 29.23% | 34.02% | |
| Max daily dropi | 29.77% | 17.71% | |
| Max wkly dropi | 39.59% | 17.74% | |
| 10Y | Growthi | +747.26% | -30.40% |
| CAGRi | +23.83% | -3.56% | |
| Volatilityi | 65.53% | 35.05% | |
| Sharpe ratioi | 0.58 | -0.05 | |
| Sortino ratioi | 0.89 | -0.07 | |
| Max drawdowni | 73.78% | 62.09% | |
| Current drawdowni | 22.42% | 49.23% | |
| Avg drawdowni | 26.94% | 29.89% | |
| Ulcer Indexi | 32.18% | 34.25% | |
| Max daily dropi | 39.94% | 35.28% | |
| Max wkly dropi | 48.27% | 38.91% |
| Category | PTCT | BMRN |
|---|---|---|
| Company | PTC Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | A biopharmaceutical company focused on treatments for rare genetic disorders, including Duchenne muscular dystrophy therapies and gene therapy programs for neurological and metabolic conditions. | A biotechnology company specializing in therapies for rare genetic diseases, with an established portfolio addressing phenylketonuria, achondroplasia, and other inherited metabolic and skeletal conditions. |
| Investor focus | Commercial uptake of approved rare disease therapies, regulatory milestones for pipeline gene therapy candidates, and royalty or partnership revenue contribution. | Growth of newer franchise launches, pricing and access dynamics for high-cost rare disease drugs, and pipeline expansion into adjacent rare disease indications. |
- Established commercial presence in Duchenne muscular dystrophy gives the company a foothold in a niche but high-need treatment category
- Diversified pipeline spanning gene therapy and small-molecule approaches spreads regulatory and clinical risk across multiple modalities
- Global commercial infrastructure supports launches across both US and international rare disease markets
- Longer operating history in rare disease drug development has produced a broader base of approved, revenue-generating therapies
- Leadership position in achondroplasia treatment addresses a condition with limited historical treatment options
- Scale advantages in manufacturing and global distribution support consistent supply for chronically dependent patient populations
- Regulatory setbacks or label restrictions on rare disease therapies can materially affect commercial trajectories given the smaller patient populations involved
- Reliance on a concentrated set of rare disease franchises leaves earnings more exposed to any single product's performance
- Payer negotiations for high-priced rare disease treatments can pressure realized pricing and reimbursement timelines
- Maturing legacy products may see slower growth as newer competitors and biosimilar-like alternatives emerge over time
- Rare disease drug pricing remains a recurring target for policy scrutiny and payer pushback
- Pipeline expansion into new indications carries the typical binary risk of clinical trial outcomes
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.